Sequana Medical N.V. (SEQUA.BR)
Sequana Medical N.V. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Gent, BE. The stock last traded at $0.61, up 0.00% on the session, giving a market capitalisation of $47.8M. Its beta of -0.29 implies it has historically moved less than the broad market.
Sequana Medical N.V. is a medical technology company that has reached the commercial stage, dedicated to creating innovative solutions for managing excessive fluid accumulation linked to liver conditions, malignant ascites, and heart failure. The company's key offerings include the alfapump® system, an implanted device specifically designed to treat severe and resistant liver ascites as well as malignant ascites (fluid buildup caused by cancer). Additionally, it provides Direct Sodium Removal (DSR) technology to address ongoing fluid congestion in patients with heart failure. This DSR technology is integrated into the alfapump® DSR system, a fully implantable solution for direct sodium removal therapy in heart failure patients experiencing fluid overload. Established in 2006 and headquartered in Ghent, Belgium, Sequana Medical operates across Belgium, Germany, France, Switzerland, and other international regions.
Sequana Medical N.V. is most often compared with the following Healthcare names: